News

Feds recommend pausing vaccine for mosquito-borne disease chikungunya in people over 60
The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...
After 2 reported deaths, officials tell Ixchiq users age 60+ to stop vaccine temporarily
The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...
MedPage Today2d
FDA/CDC Call Time Out on Ixchiq Vaccine for Older Adults
Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...
2VALN : US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For...
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...
BioPharma Dive2d
FDA follows EMA in limiting use of Valneva shot
Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...
Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance
Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...